<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; issue</title>
	<atom:link href="http://www.tapanray.in/tag/issue/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>‘Data Protection’: Needs A Clear Direction…But Is It An IPR Issue?</title>
		<link>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue</link>
		<comments>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/#comments</comments>
		<pubDate>Mon, 02 Mar 2015 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[39.3]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Charles]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Clift]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[plus]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Satwant]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6397</guid>
		<description><![CDATA[The terminologies ‘Data Exclusivity’ and ‘Data Protection’ are quite often used interchangeably by many, creating a great deal of confusion on the subject. However, in a true sense these are quite different issues having critical impact on public health interest &#8230; <a href="http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent Conundrum: Ignoring India Will Just Not be Foolhardy, Not An Option Either</title>
		<link>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either</link>
		<comments>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/#comments</comments>
		<pubDate>Mon, 29 Apr 2013 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Enticing]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[exit]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foolhardy]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Lamy]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[lucrative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[opposition]]></category>
		<category><![CDATA[option]]></category>
		<category><![CDATA[Pascal]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[post]]></category>
		<category><![CDATA[pre]]></category>
		<category><![CDATA[PwC]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transfer]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2267</guid>
		<description><![CDATA[The recent verdict of the Supreme Court against Novartis, upholding the decision of the Indian Patent Office (IPO) against grant of patent to their cancer drug Glivec, based on Section 3(d) of the Indian Patents Act, has caused a flutter &#8230; <a href="http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Maira Committee’ delivers: Resolves 100% FDI issue in the pharma sector of India</title>
		<link>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india</link>
		<comments>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/#comments</comments>
		<pubDate>Mon, 17 Oct 2011 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[delivers]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Maira]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Resolves]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=187</guid>
		<description><![CDATA[On October 10, 2011, Dr Man Mohan Singh, the Prime Minister of India accepted the recommendation of the ‘Maira Committee’ on Foreign Direct Investment (FDI) in the Pharmaceutical Sector of India and decided that the Competition Commission of India (CCI) &#8230; <a href="http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Deadly ‘Superbugs’: The larger issues</title>
		<link>http://www.tapanray.in/deadly-superbugs-the-larger-issues/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deadly-superbugs-the-larger-issues</link>
		<comments>http://www.tapanray.in/deadly-superbugs-the-larger-issues/#comments</comments>
		<pubDate>Mon, 11 Apr 2011 00:30:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Deadly]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[larger]]></category>
		<category><![CDATA[ministry of health]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[MRSA]]></category>
		<category><![CDATA[NDM1]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Superbugs]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=277</guid>
		<description><![CDATA[Every year, April 7 is observed as ‘World Health Day’ across the globe. This year, 2011, is no exception. However, interestingly considering the increasing debate on the antibiotic resistance ‘Superbug’, the theme of this year has been very aptly coined &#8230; <a href="http://www.tapanray.in/deadly-superbugs-the-larger-issues/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deadly-superbugs-the-larger-issues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The issue of ‘Counterfeit Drugs’ in India: An “Ostrich Syndrome’</title>
		<link>http://www.tapanray.in/the-issue-of-counterfeit-drugs-in-india-an-ostrich-syndrome/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-issue-of-counterfeit-drugs-in-india-an-ostrich-syndrome</link>
		<comments>http://www.tapanray.in/the-issue-of-counterfeit-drugs-in-india-an-ostrich-syndrome/#comments</comments>
		<pubDate>Mon, 14 Feb 2011 00:30:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ACTA]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Dubai]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[hazard]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Ostrich]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[related]]></category>
		<category><![CDATA[Syndrome]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trademark]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=302</guid>
		<description><![CDATA[Ellen‘t Hoen, former Policy Advocacy Director of MSF’s Campaign for Access to Essential Medicines wrote in April 2009 as follows: “People often seem to confuse counterfeit, substandard and generic medicines – using the terms interchangeably. But they are very separate &#8230; <a href="http://www.tapanray.in/the-issue-of-counterfeit-drugs-in-india-an-ostrich-syndrome/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-issue-of-counterfeit-drugs-in-india-an-ostrich-syndrome/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Access to affordable healthcare to 65% of Indian population still remains a key issue even after six decades of independence of the country.</title>
		<link>http://www.tapanray.in/access-to-affordable-healthcare-to-65-of-indian-population-still-remains-a-key-issue-even-after-six-decades-of-independence-of-the-country/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=access-to-affordable-healthcare-to-65-of-indian-population-still-remains-a-key-issue-even-after-six-decades-of-independence-of-the-country</link>
		<comments>http://www.tapanray.in/access-to-affordable-healthcare-to-65-of-indian-population-still-remains-a-key-issue-even-after-six-decades-of-independence-of-the-country/#comments</comments>
		<pubDate>Mon, 12 Apr 2010 01:30:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[65%]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[after]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[decades]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Even]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[independence]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remains]]></category>
		<category><![CDATA[six]]></category>
		<category><![CDATA[still]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=442</guid>
		<description><![CDATA[Despite so much of stringent government control, debate and activism on the affordability of modern medicines in India, on the one hand, and the success of the government to make medicines available in the country at a price, which is &#8230; <a href="http://www.tapanray.in/access-to-affordable-healthcare-to-65-of-indian-population-still-remains-a-key-issue-even-after-six-decades-of-independence-of-the-country/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/access-to-affordable-healthcare-to-65-of-indian-population-still-remains-a-key-issue-even-after-six-decades-of-independence-of-the-country/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Union Budget 2010-11…the issue of improving access to healthcare…encouraging innovation… and beyond</title>
		<link>http://www.tapanray.in/the-union-budget-2010-11the-issue-of-improving-access-to-healthcareencouraging-innovation-and-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-union-budget-2010-11the-issue-of-improving-access-to-healthcareencouraging-innovation-and-beyond</link>
		<comments>http://www.tapanray.in/the-union-budget-2010-11the-issue-of-improving-access-to-healthcareencouraging-innovation-and-beyond/#comments</comments>
		<pubDate>Mon, 08 Mar 2010 01:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2010-11]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[encouraging]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Improving]]></category>
		<category><![CDATA[incentive]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=458</guid>
		<description><![CDATA[The Primary role of the pharmaceutical industry in India, like in many other countries of the world, is to make significant contribution to the healthcare objectives of the nation by meeting the needs of the ailing patients through improved access &#8230; <a href="http://www.tapanray.in/the-union-budget-2010-11the-issue-of-improving-access-to-healthcareencouraging-innovation-and-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-union-budget-2010-11the-issue-of-improving-access-to-healthcareencouraging-innovation-and-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does the Indian Patents Act conform to Article 27 (Patentable Subject Matter) of TRIPS on the issue of ‘local working of patents’?</title>
		<link>http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents</link>
		<comments>http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/#comments</comments>
		<pubDate>Mon, 22 Feb 2010 01:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[27]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Article]]></category>
		<category><![CDATA[conform]]></category>
		<category><![CDATA[Does]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[Matter]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Patentable]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Subject]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=464</guid>
		<description><![CDATA[India is one of the signatories of TRIPS and has a national commitment on adherence to this important international agreement. It is, therefore, widely believed that the amended Indian Patents Act will be TRIPS compliant. A recent circular from CGPTD: &#8230; <a href="http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-the-indian-patents-act-conform-to-article-27-patentable-subject-matter-of-trips-on-the-issue-of-local-working-of-patents/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>IPR, Climate Change and addressing the issue of transfer of Carbon abatement technology in the developing world.</title>
		<link>http://www.tapanray.in/ipr-climate-change-and-addressing-the-issue-of-transfer-of-carbon-abatement-technology-in-the-developing-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ipr-climate-change-and-addressing-the-issue-of-transfer-of-carbon-abatement-technology-in-the-developing-world</link>
		<comments>http://www.tapanray.in/ipr-climate-change-and-addressing-the-issue-of-transfer-of-carbon-abatement-technology-in-the-developing-world/#comments</comments>
		<pubDate>Mon, 23 Nov 2009 01:30:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abatement]]></category>
		<category><![CDATA[addressing]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Carbon]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Climate]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[green]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[transfer]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=718</guid>
		<description><![CDATA[To address all pervasive global challenge of climate change, access to efficient and cost effective carbon abatement technology to reduce the greenhouse effect has become a very important issue, especially for an emerging economy like, India. This issue perhaps will &#8230; <a href="http://www.tapanray.in/ipr-climate-change-and-addressing-the-issue-of-transfer-of-carbon-abatement-technology-in-the-developing-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ipr-climate-change-and-addressing-the-issue-of-transfer-of-carbon-abatement-technology-in-the-developing-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tackling the menace of counterfeit medicines – vested interests or petty sentiments should not make the pressing public healthcare issue irrelevant.</title>
		<link>http://www.tapanray.in/tackling-the-menace-of-counterfeit-medicines-vested-interests-or-petty-sentiments-should-not-make-the-pressing-public-healthcare-issue-irrelevant/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=tackling-the-menace-of-counterfeit-medicines-vested-interests-or-petty-sentiments-should-not-make-the-pressing-public-healthcare-issue-irrelevant</link>
		<comments>http://www.tapanray.in/tackling-the-menace-of-counterfeit-medicines-vested-interests-or-petty-sentiments-should-not-make-the-pressing-public-healthcare-issue-irrelevant/#comments</comments>
		<pubDate>Mon, 29 Jun 2009 00:30:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[interests]]></category>
		<category><![CDATA[irrelevant. pharmaceuticals]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[or]]></category>
		<category><![CDATA[petty]]></category>
		<category><![CDATA[pressing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sentiments]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Tackling]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[vested]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=848</guid>
		<description><![CDATA[There are following three clearly emerging views on the global issue of counterfeit drugs:1. The innovator companies feel that the generic pharmaceutical industry and the drug regulators are not really very keen to effectively address and resolve this global public &#8230; <a href="http://www.tapanray.in/tackling-the-menace-of-counterfeit-medicines-vested-interests-or-petty-sentiments-should-not-make-the-pressing-public-healthcare-issue-irrelevant/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/tackling-the-menace-of-counterfeit-medicines-vested-interests-or-petty-sentiments-should-not-make-the-pressing-public-healthcare-issue-irrelevant/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
